Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INBRX-109 versus placebo in unresectable or metastatic conventional chondrosarcoma
NL-OMON54090Phase 2Recruiting
- Sponsor
- Inhibrx, Inc.
- Start
- Jul 2022
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in conventional chondrosarcoma comparing INBRX-109 with Placebo (2 arms). Primary endpoint: Progression-free survival. Started Jul 2022; status: recruiting.
02
Drugs
ozekibart
03
Conditions
conventional chondrosarcoma
Beyond the preview
Go deeper on NL-OMON54090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54090.